A certificate of analysis (COA) is one of the most important documents a researcher can review before incorporating a peptide into laboratory work. It provides a standardized summary of analytical testing results that confirm a peptide's identity, purity, and compositional quality, the foundational data points that directly affect experimental reproducibility.

Yet despite its importance, the COA is frequently misunderstood.

Researchers may glance at a purity percentage without understanding the analytical method behind it, or overlook critical distinctions (such as the difference between HPLC purity and net peptide content) that can significantly impact how a compound performs in controlled assays.

This content is provided for informational and educational purposes only and does not constitute medical, pharmaceutical, or legal advice. The products discussed are intended for laboratory research purposes only and are not for human or animal consumption. They are not intended to diagnose, treat, cure, or prevent any disease.

This article examines the key components of a peptide COA, explains the analytical methods used to generate each data point, and outlines what researchers should look for, and question, when evaluating documentation from any supplier.

What Is a Certificate of Analysis?

A certificate of analysis is a formal quality control document issued alongside a synthesized peptide that records the results of analytical testing performed on a specific batch.

In an educational context, it functions as a batch-level report card: a structured set of measurements confirming that the material matches its stated specifications.

COAs are standard practice across the chemical and pharmaceutical sciences. The United States Pharmacopeial Convention (USP) has published official monographs and general chapters providing quality standards for peptide products, with physical reference standards procured, tested, and confirmed with assigned values that are used alongside published methodologies to evaluate drug product quality (McCarthy et al., Pharmaceutical Research, 2023).

While the RUO (Research Use Only) context differs from pharmaceutical manufacturing, the underlying analytical principles remain the same.

A well-constructed COA typically includes several core sections:

• Identity confirmation via mass spectrometry

• Purity assessment via chromatography

• Net peptide content data

• Physical appearance and storage recommendations

• Batch or lot identification numbers

Purity Assessment: The Role of HPLC

The purity percentage reported on a COA is one of the first metrics most researchers examine, and one of the most frequently misinterpreted.

How HPLC Purity Is Determined

Purity is most commonly assessed using reversed-phase high-performance liquid chromatography (RP-HPLC), a technique that separates peptide mixtures based on differences in hydrophobicity.

The sample is passed through a chromatographic column, and different compounds elute at different retention times. A detector, typically measuring UV absorption at 210–220 nm, records each component as a peak on a chromatogram (Mant et al., Methods in Molecular Biology, 2007).

The purity percentage is then calculated as the area of the main peak (the target peptide) relative to the total area of all detected peaks.

A peptide reported at 98.5% purity, for example, means that 98.5% of all UV-absorbing material in the sample corresponds to the intended compound, with the remaining 1.5% attributed to related impurities.

What HPLC Purity Does and Does Not Reveal

HPLC is highly effective at detecting peptidic impurities, including truncated sequences, deletion peptides (missing one or more amino acid residues), incompletely deprotected sequences, and synthesis byproducts. These are among the most common contaminants in synthetic peptide preparations (Elsayed et al., Journal of Peptide Science, 2025).

However, HPLC purity has important limitations.

It measures only UV-absorbing species, meaning water, salts, and counter-ions (such as trifluoroacetate, or TFA) are invisible to the detector. This is precisely why HPLC purity and net peptide content are two distinct measurements, a point explored in detail below.

Additionally, HPLC cannot confirm sequence identity on its own. A peptide missing a single amino acid may produce a chromatographic profile that appears nearly identical to the target compound.

This is why mass spectrometry data is considered an essential complement to HPLC results.

What Purity Levels Mean in Practice

In laboratory research contexts, purity thresholds are generally understood along a spectrum:

• ≥98%: Widely considered suitable for quantitative assays, structural studies, and sensitive biological work

• 95–97%: Standard for most discovery-phase laboratory investigations

• Below 95%: May introduce confounding variables in precision-dependent experiments, as impurities at that level can compete with or mask the behavior of the target peptide in controlled assays

Identity Confirmation: Mass Spectrometry

If HPLC answers the question "how pure is the sample?", mass spectrometry (MS) answers "what is the sample?"

These two techniques serve complementary analytical functions, and together they form the evidentiary backbone of a reliable COA.

How Mass Spectrometry Works in Peptide Analysis

Mass spectrometry determines the molecular weight of a compound with high precision by measuring the mass-to-charge ratio (m/z) of ionized molecules.

For peptide analysis, electrospray ionization mass spectrometry (ESI-MS) is one of the most commonly used methods, though matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS is also widely employed (Elsayed et al., Journal of Peptide Science, 2025).

The COA will typically report both values side by side: the theoretical (expected) molecular weight, calculated from the peptide's amino acid sequence, and the observed molecular weight from MS analysis.

A close match between these two values confirms that the peptide contains the expected amino acid residues in the correct quantity.

Interpreting MS Data on a COA

When reviewing the MS section of a COA, researchers should look for the observed mass (often reported as the [M+H]⁺ value for singly protonated ions) and compare it against the theoretical mass.

High‑resolution mass spectrometers can achieve mass accuracy within a few parts per million, while lower‑resolution instruments used in many routine COAs may show larger deviations. Minor adduct peaks, such as sodium [M+Na]⁺ or potassium [M+K]⁺ additions, are normal and expected.

A significant discrepancy between observed and expected mass, however, is a meaningful red flag.

It may indicate that the wrong peptide was synthesized, that a critical residue was substituted, or that a major structural modification occurred during synthesis or storage. In such cases, tandem MS (MS/MS) sequencing may be warranted to determine the identity of unexpected components.

It is worth noting that standard MS analysis confirms the total molecular weight but cannot distinguish between certain isobaric amino acids. Leucine and isoleucine, for example, have nearly identical masses and fragmentation patterns. High-resolution MS/MS can address this limitation, though it is not always included in standard COA testing.

Net Peptide Content: The Often-Overlooked Metric

One of the most consequential distinctions in peptide quality documentation is the difference between HPLC purity and net peptide content.

These are two independent measurements, and conflating them can lead to significant errors in laboratory work.

Defining Net Peptide Content

Net peptide content (NPC) represents the fraction of a lyophilized peptide sample that is actual peptide material, excluding non-peptide components such as water, counter-ions, and residual salts.

After purification by RP-HPLC, synthetic peptides are typically delivered as trifluoroacetate (TFA) salts, where TFA acts as a counter-ion to protonated amine groups within the peptide structure. Residual moisture from the lyophilization process further reduces the proportion of active peptide in the total sample weight.

As a result, net peptide content typically falls between 60% and 90% of the gross (total) sample weight, even when HPLC purity is very high.

A peptide can be 99% pure by HPLC and still have a net peptide content of only 75%, because the remaining 25% of the vial's weight consists of water and counter-ions that HPLC cannot detect (AmbioPharm, 2022).

Why the Distinction Matters

For researchers conducting quantitative work, the practical consequence is direct: if one assumes that the entire gross weight of a peptide sample is active compound, molar concentration calculations will be incorrect.

The accurate calculation requires accounting for both the net peptide content and the HPLC purity:

Molar amount of target peptide = Gross weight × NPC (%) × HPLC purity (%) / Molecular weight

For example, a 5 mg vial of a peptide with 85% NPC, 98.7% HPLC purity, and a molecular weight of 1,060 g/mol contains approximately 4.20 mg (3.96 μmol) of the actual target compound, not 5 mg.

How Net Peptide Content Is Measured

NPC is determined through methods distinct from HPLC, most commonly amino acid analysis (AAA), elemental analysis, or UV spectrophotometry.

AAA involves hydrolyzing the peptide into its constituent amino acids, derivatizing them, and quantifying each by chromatographic separation.

Elemental analysis measures nitrogen content (since counter-ions and water do not contain nitrogen) to calculate the peptide fraction of the total sample mass.

Not all COAs include net peptide content data, particularly at the RUO level. When this information is absent, researchers should be aware that the reported gross weight may overstate the amount of active peptide present.

Additional COA Components

Beyond the three primary analytical pillars of HPLC purity, MS identity, and net peptide content, a thorough COA may include several additional data points that contribute to a complete quality picture.

Physical Appearance

The COA will typically note the visual appearance of the peptide, most commonly described as a white to off-white lyophilized powder.

While this may seem like a superficial observation, visible discoloration, unusual texture, or signs of moisture can indicate degradation, improper storage, or contamination during manufacturing.

Batch and Lot Identification

Every COA should carry a unique batch or lot number that ties the analytical data to a specific production run.

This is essential for traceability. If experimental results vary between orders of the same peptide, batch-level identification allows researchers to investigate whether the material itself has changed.

It also enables communication with the supplier about specific lots if quality concerns arise.

Storage and Handling Recommendations

Peptide stability is affected by temperature, moisture, and light exposure.

COAs commonly specify storage conditions, such as maintaining the lyophilized material at −20°C in a dry environment, that reflect the compound's known stability characteristics.

These recommendations are grounded in accelerated stability testing methodologies, where peptides are subjected to thermal stress at multiple temperatures to model long-term degradation behavior (McCarthy et al., Pharmaceutical Research, 2023).

Residual Solvents

Solvents used during synthesis and purification can persist in trace amounts in the final product.

Some COAs include residual solvent analysis, performed via gas chromatography, to verify that concentrations of compounds such as acetonitrile, dichloromethane, or dimethylformamide fall within established safety thresholds (Biosynth, n.d.).

Salt Form and Counter-Ion Information

The salt form of a peptide (most commonly TFA salt, though acetate and hydrochloride forms are also used) affects both the gross weight and solubility characteristics of the compound.

This information, when included on a COA, helps researchers select appropriate solvents and adjust concentration calculations.

How to Evaluate a COA: Key Questions for Researchers

Not all COAs are created equal. The depth and transparency of analytical documentation varies significantly across suppliers.

When evaluating a COA in an educational or research planning context, the following questions provide a useful framework.

Is the Testing Methodology Specified?

A COA that reports "98% purity" without specifying the analytical method used (the HPLC column type, mobile phase, detection wavelength, or gradient conditions) provides less actionable information than one that includes chromatographic method details.

Validated analytical methods, and where relevant alignment with guidelines such as ICH Q6B for biotechnological and biological products, produce more defensible and reproducible data (ICH, 1999).

Are Chromatograms and Spectra Included?

The most transparent COAs include the actual HPLC chromatogram and MS spectrum as part of the report, rather than simply listing numerical values.

A chromatogram allows the researcher to visually assess peak shape, resolution, and the presence of any secondary peaks. A clean chromatogram with a single dominant peak comprising 95–99% of the total area is generally expected for research-grade material.

If the COA provides only a single purity number with no supporting analytical data, that is a limitation worth noting.

Does the COA Include a Certifying Authority?

A COA signed or certified by a qualified analyst or chemist adds a layer of accountability to the data.

This level of documentation and formal certification is standard in pharmaceutical and GMP‑grade environments; for RUO‑grade peptide suppliers it represents a higher‑end practice rather than an industry‑wide standard

Is the COA Batch-Specific?

A COA should correspond to a specific lot or batch of material.

Generic or template-style COAs that are not tied to individual production runs do not provide the same level of quality assurance as batch-specific documentation.

Common Synthesis Impurities Detected by COA Testing

Understanding what kinds of impurities analytical testing can detect, and where they originate, provides additional context for interpreting COA data.

The most common impurities in synthetic peptides include:

• Deletion sequences: peptides missing one or more amino acid residues due to incomplete coupling during synthesis

• Truncated sequences: peptides where synthesis terminated prematurely

• Incompletely deprotected sequences: where protecting groups used during solid-phase synthesis were not fully removed during the cleavage step

• Deamidation products: a chemical modification where asparagine residues convert to aspartate, adding approximately 1 dalton to the molecular mass, which can occur during synthesis or storage under suboptimal conditions (Elsayed et al., Journal of Peptide Science, 2025)

These impurities are typically present in small amounts in well-purified preparations.

However, when present at higher levels, they can compete with or obscure the behavior of the target peptide in experimental assays, potentially leading to irreproducible or misleading results.

The Broader Context: Why COA Literacy Matters

The certificate of analysis sits at the intersection of analytical chemistry, quality control, and research integrity.

For laboratory investigators, the ability to read and critically evaluate a COA is not merely a procurement skill. It is a methodological competency that directly affects the reliability of downstream experimental data.

Regulatory bodies including the FDA, ICH, and EMA have established frameworks for the analysis, stability testing, and quality control of peptide compounds. The ICH Q6B guidelines serve as a key reference for evaluating parameters such as purity and stability, with stability data being integral to determining shelf life and assessing potential degradation pathways (ICH, 1999).

While RUO peptides are not subject to the same regulatory requirements as pharmaceutical products, the analytical principles and quality expectations documented in these frameworks provide a useful benchmark for evaluating supplier documentation.

In a research supply landscape where documentation quality varies widely, COA literacy equips researchers to make more informed decisions about the materials they bring into the laboratory, and to identify gaps in documentation before they become gaps in experimental validity.

Frequently Asked Questions

What is a certificate of analysis (COA) for a peptide?

A certificate of analysis is a quality control document that accompanies a specific batch of synthesized peptide, reporting the results of analytical testing for identity, purity, and composition. 

What is the difference between HPLC purity and net peptide content?

HPLC purity measures the proportion of the target peptide relative to other peptidic impurities in the sample, assessed by chromatographic separation and UV detection.

Net peptide content measures the proportion of actual peptide material in the total sample weight, excluding non-peptide components such as water, counter-ions, and salts.

A peptide can have high HPLC purity (e.g., 99%) but a lower net peptide content (e.g., 75%) because the remaining weight consists of moisture and counter-ions that HPLC does not detect.

Why does mass spectrometry matter if HPLC already shows high purity?

HPLC and mass spectrometry answer different analytical questions.

HPLC quantifies how pure the sample is by separating its components, but it cannot confirm what the compound is. A peptide with a single amino acid deletion may appear pure on HPLC while having an incorrect sequence.

Mass spectrometry confirms the molecular identity by measuring the exact mass of the compound, verifying that it matches the expected molecular weight for the target sequence.

What does "Research Use Only" mean on a peptide COA?

Research Use Only (RUO) indicates that a product is intended exclusively for laboratory research purposes.

RUO products are not approved for human or animal use and are not intended to diagnose, treat, cure, or prevent any disease.

RUO-grade COAs typically include HPLC purity and MS identity data but may not include all tests required for pharmaceutical or GMP-grade materials.

What should I look for when evaluating a peptide COA?

Key elements to review include:

• The HPLC purity percentage and whether the analytical method is specified

• Mass spectrometry data showing agreement between observed and theoretical molecular weight

• Net peptide content, if available

• Batch or lot number for traceability

• Storage recommendations

• Whether supporting analytical data (chromatograms, spectra) are included rather than summary numbers alone

Key Takeaways

A certificate of analysis is the primary quality control document for any synthesized peptide.

Its core components, HPLC purity, mass spectrometric identity confirmation, and net peptide content, each serve distinct analytical functions that together provide a comprehensive quality profile.

HPLC purity quantifies the target peptide relative to synthesis-related impurities. Mass spectrometry confirms molecular identity by verifying the compound's exact mass against its theoretical value. Net peptide content accounts for non-peptide components in the sample weight, a distinction essential for accurate concentration calculations in quantitative laboratory work.

The quality, transparency, and completeness of COA documentation varies across suppliers. Researchers benefit from evaluating not just the reported numbers, but the analytical methods, supporting data, and batch-level specificity behind them.

This content is provided for informational and educational purposes only. All products referenced are intended for laboratory research purposes only and are not for human or animal consumption.